Treace Medical Q2 net loss narrows to $15.9 million; revenue falls 4% to $45.4 million
TMCI•Second-quarter results
Treace Medical Concepts posted second-quarter 2026 revenue of $45.4 million, down 4% year over year.
GAAP net loss narrowed to $15.9 million, or $0.24 per share.
Non-GAAP adjusted EBITDA loss was $3.5 million.
Cash position, outlook and product updates
Cash, cash equivalents and marketable securities totaled $45.6 million at June 30, 2026; year-to-date cash usage fell 57%.
The company raised its 2026 revenue outlook to $204 million-$212 million.
Treace also launched a limited release of SuperBite and completed its first HyperPlate XM case.
